Clinical Trial Update: Assessment of Anti-RANKL Antibody in Post-menopausal Women [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an anti-RANKL antibody in postmenopausal women with osteoporosis; sponsor Jiangsu T-Mab Biopharma Co.,Ltd, status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• anti-RANKL antibody

Snippet

Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd | Conditions: Osteoporosis | Phase 1 | Status: UNKNOWN